Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Medical Developments International Builds Penthrox Momentum on Improved Cash Flow
Medical Developments International ups FY26 revenue 9% to $42.6m; Penthrox demand boosts cash flow; paediatric approval expands UK/Europe use, driving momentum.
Latest Stories — SECTOR DESK
Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm
Recce expands Phase 3 diabetic foot infection trial with R327G active comparator arm, pursuing non-inferiority vs antibiotics; interim data after 104 patients.
Entropy Neurodynamics Appoints BioCina for Global Manufacture of TRP-8803 IV Psilocin
Entropy Neurodynamics appoints BioCina for global manufacture of TRP-8803 IV psilocin, enabling regulatory submissions and rapid scale-up across indications.
Vita Life Sciences Delivers Record First Half on Improved Product Mix and Margin Increase
Vita Life Sciences hits record H1: revenue $48.3m, NPAT $5.5m, margin up to 63.5%; declares 5.0c dividend; $33.7m cash, no borrowings amid China headwinds.
OncoSil Medical Receives FDA Exemption Approval for Targeted Radiation Device
OncoSil wins FDA humanitarian device exemption for dCCA, unlocking US market ~1,000 patients/year and $80m TAM; launch set for H2 2027.
Proteomics International Laboratories Secures Australian Patent Acceptance for PromarkerEndo
Proteomics International wins IP Australia acceptance for PromarkerEndo, extending protection to 2041 and boosting local commercialization and licensing talks.
Anteris Technologies Expands PARADIGM Trial as US Recruitment Begins
Anteris Technologies expands PARADIGM trial as US recruitment kicks off; Medicare reimbursement secured, accelerating path to DurAVR THV commercialisation.
Alterity Therapeutics Granted ATH434 Patent to Treat Neurodegenerative Diseases
Alterity Therapeutics wins US patent for ATH434, extending protection to 2045 and backing Phase 3 push in MSA/Parkinsons, lifting ATH upside.
LTR Pharma Reports 93% SPONTAN Response in Real-World ED Cohort
LTR Pharma reports 93% real-world ED response to SPONTAN in treatment-experienced men, largest cohort to date, fueling ROXUS US plans.
Austco Healthcare Extends Direct Sales Presence with Acquisition of Nurse Call Platform Reseller
Austco to acquire MCS, bringing nurse-call in-house; boosts direct sales, adds $1.88m revenue and $0.82m EBITDA, earnings-accretive.
AVITA Medical Lifts Guidance as Record Quarter Brings Cash Flow Breakeven into View
AVITA Medical lifts 2026 revenue guidance after record Q2 US$21.7m; eyes cash-flow breakeven in Q4 as RECELL-led growth broadens international reach.
Clarity Pharmaceuticals Adds Two Complete Responses to SECuRE Trial Data
Clarity Pharma reports two new complete responses at 8GBq in SECuRE trial, boosting radiographic disease control to seven; PSA declines strong.